Hayashi K, Nunami K, Kato J, Yoneda N, Kubo M, Ochiai T, Ishida R
Research Laboratory of Applied Biochemistry and Safety Research Laboratory, Tanabe Seiyaku Co., Ltd., Osaka, Japan.
J Med Chem. 1989 Feb;32(2):289-97. doi: 10.1021/jm00122a003.
(4S)-1-Alkyl-3-[[N-(carboxyalkyl)amino]acyl]-2-oxoimidazolidine-4- carboxylic acid derivatives (3) were prepared by two methods. Their angiotensin converting enzyme (ACE) inhibitory activities and antihypertensive effects were evaluated, and the structure-activity relationships were discussed. The dicarboxylic acids 3a-n possessing S,S,S configuration showed potent in vitro ACE inhibitory activities with IC50 values of 1.1 X 10(-8)-1.5 X 10(-9) M. The most potent compound in this series, monoester 3p, had an ID50 value of 0.24 mg/kg, po for inhibition of angiotensin I induced pressor response in normotensive rats and produced a dose-dependent decrease in systolic blood pressure of spontaneously hypertensive rats (SHRs) at doses of 1-10 mg/kg, po.
(4S)-1-烷基-3-[[N-(羧基烷基)氨基]酰基]-2-氧代咪唑烷-4-羧酸衍生物(3)通过两种方法制备。评估了它们的血管紧张素转换酶(ACE)抑制活性和降压作用,并讨论了构效关系。具有S,S,S构型的二羧酸3a-n在体外显示出强效的ACE抑制活性,IC50值为1.1×10(-8)-1.5×10(-9)M。该系列中最有效的化合物单酯3p,对正常血压大鼠中血管紧张素I诱导的升压反应的抑制作用的口服半数抑制剂量(ID50)值为0.24mg/kg,并且在1-10mg/kg口服剂量下使自发性高血压大鼠(SHRs)的收缩压产生剂量依赖性降低。